No Virological Failure in Semen During Properly Suppressive Antiretroviral Therapy Despite Subtherapeutic Local Drug Concentrations

Abstract Purpose: The aim of the study was to investigate whether drug resistance occurs earlier in seminal than in blood plasma with the use of such HAART regimens, of which only the two NRTIs achieve therapeutic concentrations in seminal plasma. Method: Seminal and blood plasma of 12 patients, for 48–96 weeks on suppressive first-line therapy with saquinavir/ritonavir/didanosine/lamivudine, nelfinavir/didanosine/stavudine, or efavirenz/lamivudine/zidovudine were prospectively evaluated for HIV-1-RNA resistance mutations and drug concentrations. Results: Saquinavir, nelfinavir, and efavirenz blood plasma concentrations were in the therapeutic range. Nelfinavir and efavirenz seminal plasma concentrations were below the limit of quantification. In only 2 of 9 seminal plasma samples, from 1 of 6 patients, the saquinavir concentration was above the minimum therapeutic level. The seminal plasma HIV-1-RNA concentration remained undetectable in all patients up to 96 weeks, and therefore drug resistance could not be demonstrated. Thus, despite suboptimal local drug concentrations, no virological failure occurred in seminal plasma after prolonged first-line HAART. Conclusion: This finding supports the hypothesis that the source of HIV in semen is a spillover from the blood/extraluminal tissue and that therefore seminal plasma drug levels may not be critical for viral suppression within the lumen of the male genital tract.

[1]  P. Vernazza.  HIV in semen: Still more to be learned , 2005, AIDS research and therapy.

[2]  K. Mayer,et al.  Human immunodeficiency virus type-1 episomal cDNA in semen , 2005, AIDS research and therapy.

[3]  I. van der Tweel,et al.  Comparison of Two Once-Daily Regimens with a Regimen Consisting of Nelfinavir, Didanosine, and Stavudine in Antiretroviral Therapy-Naïve Adults: 48-Week Results from the Antiretroviral Regimen Evaluation Study (ARES) , 2005, HIV clinical trials.

[4]  P. Reiss,et al.  Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. , 2004, AIDS.

[5]  D. Burger,et al.  Simultaneous Determination of the HIV Drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the Nelfinavir Hydroxymetabolite M8, and Nevirapine in Human Plasma by Reversed-Phase High-Performance Liquid Chromatography , 2003, Therapeutic drug monitoring.

[6]  C. Solas,et al.  Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients , 2003, Antimicrobial Agents and Chemotherapy.

[7]  P. Reiss,et al.  The influence of efavirenz on the pharmacokinetics of a twice‐daily combination of indinavir and low‐dose ritonavir in healthy Volunteers , 2002, Clinical pharmacology and therapeutics.

[8]  D. Pillay,et al.  Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. , 2001, The Journal of antimicrobial chemotherapy.

[9]  B. Jégou,et al.  Viruses in the Mammalian Male Genital Tract and Their Effects on the Reproductive System , 2001, Microbiology and Molecular Biology Reviews.

[10]  L. Hagberg,et al.  Antiretroviral treatment of central nervous system HIV‐1 infection: a review , 2001, HIV medicine.

[11]  D. Mcclernon,et al.  Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. , 2000, AIDS research and human retroviruses.

[12]  Phalguni Gupta,et al.  Effect of Antiretroviral Therapy on HIV Shedding in Semen , 2000, Annals of Internal Medicine.

[13]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[14]  D. Pillay,et al.  Poor penetration of the male genital tract by HIV-1 protease inhibitors. , 1999, AIDS.

[15]  Hui Zhang,et al.  Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. , 1998, The New England journal of medicine.

[16]  P. Vernazza,et al.  Resistance of HIV‐1 to antiretroviral agents in blood and seminal plasma: implications for transmission , 1998, AIDS.

[17]  I. Keet,et al.  An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine , 1998, AIDS.

[18]  G. Liuzzi,et al.  A Combination of Nucleoside Analogues and a Protease Inhibitor Reduces HIV-1 RNA Levels in Semen: Implications for Sexual Transmission of HIV Infection , 1998, Antiviral therapy.

[19]  J. Sninsky,et al.  Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.

[20]  T. Merigan,et al.  Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. , 1994, The Journal of infectious diseases.

[21]  P. Vernazza,et al.  Antiretroviral therapy to reduce the sexual transmission of HIV. , 2003, Journal of HIV therapy.